Forest Devices Launches Collaboration with Alberta Health Services

CALGARY, Alberta & PITTSBURGH–(BUSINESS WIRE)–#MedTech–Medical technology pioneer Forest Devices, Inc. (FDI) and Alberta Health Services (AHS) today announced a partnership to improve healthcare delivery for stroke patients in Alberta. The goals of the broad, five-year collaboration are to evaluate, implement, and scale technologies that can improve patient outcomes and health system economics by empowering emergency health care providers to make informed decisions regarding care for stroke patients.

FDI’s stroke diagnostic platform, AlphaStroke, is the first technology that supports prehospital health care providers in identifying strokes in the field so they can make the best triage decisions for patients.

In Alberta, two comprehensive stroke hospitals and approximately 500 ambulances serve a population of over four million people living in over 650,000 square kilometers. The AHS/FDI collaboration was enabled by way of the Prehospital Stroke Diagnostics Project, which was created by AHS in 2019 with the aim of testing an innovative solution that increases the accuracy and speed of prehospital diagnosis of stroke. The project team assessed 14 technologies and ultimately determined that AlphaStroke was the most viable solution and that the vision of FDI aligned most closely with the objectives of AHS.

Annually, stroke accounts for thousands of hospitalizations in Alberta and costs over $400 million. Every minute a stroke goes untreated, 2 million neurons die. Faster and more accurate prehospital diagnosis presents the opportunity to save time and brain.

FDI CEO and Co-founder, Matt Kesinger, added “The partnership between AHS and FDI has created an exciting opportunity to expand and accelerate the development and deployment of our innovative stroke diagnostic technology. AHS has been a global leader in stroke care innovation for decades, and this collaboration represents an unparalleled opportunity to improve outcomes for patients, their families, and health systems across the world.”

“I want to commend Forest Devices, Inc. for choosing Alberta. Our province has a dynamic healthcare innovation ecosystem – and being recognized for our talent and expertise is a huge win that will spur future developments across multiple sectors of the economy. This supports our government’s strategic focus to strengthen economic development through innovation, and I look forward to what’s in store for the future,” said Tanya Fir, Alberta’s Minister of Economic Development, Trade and Tourism.

“This is our second collaboration with the Impact, Innovation & Evidence team at AHS. They have become a critical investment attraction and innovation ecosystem partner, with a demand/pull driven strategy, and an open-minded, collaborative approach.” – Christy Pierce, CEO, New West Networks – Calgary and San Francisco based team supporting the efforts of Alberta’s Economic Development, Trade & Tourism Department.

Forest Devices, Inc. is a medical device company based in Pittsburgh, Pennsylvania and Calgary, Alberta that has developed AlphaStroke, the first prehospital stroke detection technology. The company strives to reduce functional disability caused by stroke by eliminating delays in stroke treatment.

Alberta Health Services is the provincial health authority responsible for planning and delivering health supports and services for more than four million adults and children living in Alberta. Its mission is to provide a patient-focused, quality health system that is accessible and sustainable for all Albertans.

https://www.albertahealthservices.ca/
http://www.forestdevices.com/

Contacts

For press inquiries:

Carmelo R. Montalvo
412.404.3769
pr@forestdevices.com
URL: www.forestdevices.com

Staff

Recent Posts

Health Care AI Initiative Launched by Paragon Health Institute

New initiative will promote AI policies and solutions to transform American health careWASHINGTON, Jan. 12,…

43 minutes ago

Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound

Agreement expands Amphastar's proprietary peptide pipeline into broader inflammatory and autoimmune conditions RANCHO CUCAMONGA, CA…

43 minutes ago

CelLBxHealth PLC Announces Board Changes

GUILDFORD, SURREY / ACCESS Newswire / January 12, 2026 / CelLBxHealth plc (AIM:CLBX), a leader…

4 hours ago

Cosmo Enters Scale Up Phase with 104M Revenue, 128M Cash, and Breakout AI and Dermatology Platforms

Ad hoc announcement pursuant to Art. 53 LR 2025 marks a key execution year in…

5 hours ago

Pre-JPM Investor Pulse Signals 2026 Capital Rotation Toward “AI That Ships,” Admin Cost Takeout, and Differentiated Metabolic Assets With Special-Situations Capital Back in Scope

Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…

19 hours ago